Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Low risk patients, identified by low clinical scores such as (s)PESI, should be considered for early discharge to home as their mortality on ambulatory anticoagulant treatment is <1%. Studies on new oral anticoagulants (dabigatran, rivaroxaban and apixaban) - as well as results of the Hokusai-VTE trial (edoxaban) revealed during this Congress offer a new quality of treatment, including lower bleeding risk, crucial in early discharged patients.
The optimal treatment strategy in patients at intermediate risk of early death, identified by more comprehensive laboratory cardiovascular assessment, is less clear.
New data from a large prospective randomized trial suggest that patients with RV dysfunction on imaging (echo or CT) and a positive troponin I or T test could benefit from treatment with thrombolysis to prevent early haemodynamic decompensation without, however, reducing all-cause mortality and at the cost of an increased risk of stroke.
Better stratification of bleeding risk, as well as safer thrombolytic regimens are necessary to implement such a strategy in clinical practice. The potential role of low dose and/or local thrombolysis, which could also be enhanced by application of therapeutic intravascular ultrasound, awaits further research.
Session Title: Pulmonary embolism: new therapeutic strategies
© 2017 European Society of Cardiology. All rights reserved